Trial Profile
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Pharmacokinetics; Therapeutic Use
- 03 Apr 2024 Status changed from active, no longer recruiting to discontinued.
- 06 Mar 2024 Planned End Date changed from 31 Jan 2020 to 5 Mar 2025.
- 22 Jan 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Jan 2020.